Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis.
In an attempt to locate the allosteric site on muscarinic receptors to which gallamine binds, 21 residues in the putative external loops and loop/transmembrane helix interfaces have been mutated to alanine. These residues are conserved in mammalian m1-m5 receptors. All mutant receptors can be expressed in COS-7 cells at high levels and appear to be functional, in that acetylcholine binding is sensitive to GTP. The gallamine binding site does not appear to involve the first, second, and most of the third extracellular loops. Tryptophan-400 and -101 inhibit gallamine binding when mutated to alanine or to phenylalanine and may form part of the allosteric site. Several mutations also affect antagonist binding. Surprisingly, tryptophan-91, a residue conserved in monoamine and peptide receptors, is important for antagonist binding. This residue, present in the middle of the first extracellular loop, may have a structural role in many G protein-coupled receptors. Antagonist binding is also affected by mutations of tryptophan-101 and tyrosine-404 to alanine or phenylalanine. In a helical wheel model, trytophan-101 and tyrosine-404, in conjunction with serine-78, aspartate-105, and tyrosine-408, form a cluster of residues that have been reported to affect antagonist binding when mutated, and they may therefore be part of the antagonist binding site. It is suggested that the allosteric site may be located close to and just extracellular to the antagonist binding site. The binding of methoctramine, an antagonist with allosteric properties, is not substantially affected by mutations at tryptophan-91, -101, and -400 and tyrosine-404, and thus these amino acids are not important for its binding. The binding of himbacine, another antagonist with allosteric properties, is affected by these mutations but in a manner different from that of gallamine or competitive antagonists. It has not been possible to determine whether methoctramine and himbacine bind exclusively to the allosteric site or to both the competitive site and the allosteric site.
Matsui
H
H
Medical Research Council Collaborative Centre, London, England.
Lazareno
S
S
Birdsall
N J
NJ
D000109:Acetylcholine / Q000378:metabolism; D000409:Alanine / Q000235:genetics; D000494:Allosteric Regulation; D000818:Animals; D001483:Base Sequence; D001665:Binding Sites; D001667:Binding, Competitive; D005703:Gallamine Triethiodide / Q000378:metabolism; D007700:Kinetics; D008969:Molecular Sequence Data; D018727:Muscarinic Antagonists; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D019832:N-Methylscopolamine; D011976:Receptors, Muscarinic / Q000235:genetics* / Q000378:metabolism*; D012602:Scopolamine Derivatives / Q000378:metabolism; D014316:Tritium; D014364:Tryptophan / Q000235:genetics
D018727:Muscarinic Antagonists; D011976:Receptors, Muscarinic; D012602:Scopolamine Derivatives; D014316:Tritium; D014364:Tryptophan; D000109:Acetylcholine; D000409:Alanine; D005703:Gallamine Triethiodide; D019832:N-Methylscopolamine